Viatris Income from Discontinued Operations 2010-2025 | VTRS

Viatris annual/quarterly income from discontinued operations history and growth rate from 2010 to 2025. Income from discontinued operations can be defined as income or loss from the complete discontinuation of a segment or business, net of associated taxes and fees.
  • Viatris income from discontinued operations for the quarter ending March 31, 2025 was $0M, a 0% increase year-over-year.
  • Viatris income from discontinued operations for the twelve months ending March 31, 2025 was $0M, a 0% increase year-over-year.
  • Viatris annual income from discontinued operations for 2024 was $0B, a 0% decline from 2023.
  • Viatris annual income from discontinued operations for 2023 was $0B, a 0% decline from 2022.
  • Viatris annual income from discontinued operations for 2022 was $0B, a 0% decline from 2021.
Viatris Annual Income from Discontinued Operations
(Millions of US $)
2024 $0
2023 $0
2022 $0
2021 $0
2020 $0
2019 $0
2018 $0
2017 $0
2016 $0
2015 $0
2014 $0
2013 $0
2012 $0
2011 $0
2010 $0
2009 $0
Viatris Quarterly Income from Discontinued Operations
(Millions of US $)
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical Services $10.082B $14.739B
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
Stock Name Country Market Cap PE Ratio
Danaher (DHR) United States $135.269B 25.37
Elevance Health (ELV) United States $85.392B 11.02
CVS Health (CVS) United States $79.000B 9.82
Cencora (COR) United States $56.052B 19.50
DiDi Global (DIDIY) China $22.921B 34.79
Natera (NTRA) United States $22.013B 0.00
BioMerieux (BMXMF) France $15.348B 0.00
Solventum (SOLV) United States $12.566B 13.30
EUROFINS SCIENT (ERFSF) Luxembourg $12.094B 0.00
CochLear (CHEOY) Australia $11.426B 0.00
Revvity (RVTY) United States $10.766B 18.53
ICON (ICLR) Ireland $10.566B 9.82
Doximity (DOCS) United States $9.641B 44.90
Avantor (AVTR) United States $8.879B 12.90
HealthEquity (HQY) United States $8.778B 43.18
Medpace Holdings (MEDP) United States $8.445B 22.43
Sonic Healthcare (SKHHY) Australia $8.256B 0.00
Charles River Laboratories (CRL) United States $6.692B 13.11
Amplifon S.p.A (AMFPF) Italy $4.966B 27.18
Bausch + Lomb (BLCO) Canada $4.050B 23.88
BrightSpring Health Services (BTSG) United States $4.042B 37.42
Sotera Health (SHC) United States $3.463B 19.68
Alignment Healthcare (ALHC) United States $2.978B 0.00
Surgery Partners (SGRY) United States $2.933B 38.14
Concentras Parent (CON) United States $2.751B 15.90
Organon (OGN) United States $2.379B 2.53
Ardent Health Partners (ARDT) United States $2.120B 9.04
GeneDx Holdings (WGS) United States $1.998B 76.94
Premier (PINC) United States $1.885B 14.31
Progyny (PGNY) United States $1.822B 40.09
PACS (PACS) United States $1.494B 0.00
GoodRx Holdings (GDRX) United States $1.354B 27.07
Teladoc Health (TDOC) United States $1.223B 0.00
Pediatrix Medical (MD) United States $1.179B 8.97
Establishment Labs Holdings (ESTA) $1.038B 0.00
Ryman Healthcare (RYHTY) New Zealand $1.011B 0.00
CareDx (CDNA) United States $0.978B 15.27
Agilon Health (AGL) United States $0.973B 0.00
Nutex Health (NUTX) United States $0.921B 13.92
AMN Healthcare Services Inc (AMN) United States $0.810B 7.58
QDM (QDMI) Hong Kong, SAR China $0.743B 0.00
Embecta (EMBC) United States $0.617B 4.15
InnovAge Holding (INNV) United States $0.547B 0.00
Enhabit (EHAB) United States $0.525B 43.17
LifeMD (LFMD) United States $0.521B 0.00
Auna S.A (AUNA) Luxembourg $0.479B 10.78
SBC Medicals (SBC) United States $0.466B 0.00
Sonida Senior Living (SNDA) United States $0.465B 0.00
COMPASS Pathways (CMPS) United Kingdom $0.395B 0.00
Oncology Institute (TOI) United States $0.278B 0.00
Performant Healthcare (PHLT) United States $0.220B 0.00
Beauty Health (SKIN) United States $0.208B 0.00
KindlyMD (KDLY) United States $0.150B 0.00
KindlyMD (NAKA) United States $0.146B 0.00
DocGo (DCGO) United States $0.139B 22.67
OncoCyte (OCX) United States $0.095B 0.00
So-Young (SY) China $0.090B 0.00
Ascend Wellness Holdings (AAWH) United States $0.065B 0.00
Sera Prognostics (SERA) United States $0.062B 0.00
NeueHealth (NEUE) United States $0.061B 0.00
IceCure Medical (ICCM) Israel $0.057B 0.00
Biodesix (BDSX) United States $0.050B 0.00
Pheton Holdings (PTHL) China $0.039B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.032B 0.00
Basel Medical Group (BMGL) Singapore $0.019B 0.00
ModivCare (MODV) United States $0.013B 0.00
SeaStar Medical Holding (ICU) United States $0.012B 0.00
Intelligent Bio Solutions (INBS) United States $0.010B 0.00
Co-Diagnostics (CODX) United States $0.010B 0.00
BioNexus Gene Lab (BGLC) $0.006B 0.00
XWELL (XWEL) United States $0.005B 0.00
Aclarion (ACON) United States $0.004B 0.00
INVO Fertility (IVF) United States $0.004B 0.00
ISpecimen (ISPC) United States $0.003B 0.00
NewGenIvf Group (NIVF) Thailand $0.001B 0.00
Cano Health (CANOQ) United States $0.000B 0.00